ECM
NMRA icon

ExodusPoint Capital Management’s Neumora Therapeutics NMRA Stock Holding History

ExodusPoint Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$374K Buy
191,677
+10,821
+6% +$28K ﹤0.01% 1262
2025
Q4 		$324K Buy
+180,856
New +$396K ﹤0.01% 1292

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

ExodusPoint Capital Management's NMRA Position: Q1 2026 in Review

ExodusPoint Capital Management increased its Neumora Therapeutics (NMRA) stake by 6% in Q1 2026, buying an estimated $28K and bringing the position to 191,677 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

ExodusPoint Capital Management first reported a position in NMRA in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • ExodusPoint Capital Management held 191,677 shares of Neumora Therapeutics worth $374K as of Q1 2026.
  • ExodusPoint Capital Management bought 10,821 Neumora Therapeutics shares in Q1 2026, an estimated $28K.
  • Neumora Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1262 holding.
  • ExodusPoint Capital Management first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.